Redox Biol:抗生素利奈唑胺被证明危害脂肪细胞

2017-06-19 Emma MedSci原创

利奈唑胺在治疗浓度下,降低了氧化磷酸化系统的能力、影响APOE(载脂蛋白E)以及与细胞外基质相关的脂肪细胞因子和蛋白质的水平,改变了人类脂肪组织来源的干细胞的DNA甲基化水平,对脂肪细胞的正常分化和分泌造成危害。

利奈唑胺是一种已被广泛应用的,用于治疗革兰氏阳性(G+)球菌引起的感染的抗生素。为了研究利奈唑胺是否对脂肪细胞产生影响,研究人员设计实验对治疗浓度下的利奈唑胺对脂肪细胞的分泌情况进行了分析。结果显示,利奈唑胺在治疗浓度下,降低了氧化磷酸化系统的能力、影响APOE(载脂蛋白E)以及与细胞外基质相关的脂肪细胞因子和蛋白质的水平,改变了人类脂肪组织来源的干细胞的DNA甲基化水平,对脂肪细胞的正常分化和分泌造成危害。

除了是一种广泛应用的抗生素,利奈唑胺也是一种氧化磷酸化系统的外源性抑制剂。脂肪组织不仅是一个储存能量的场所,也是人体内一个非常重要的内分泌组织,脂肪细胞分泌的脂肪因子参与人体内多种代谢活动。在脂肪细胞的分化过程中,氧化磷酸化系统的正常运转非常重要,作为氧化磷酸化系统的抑制剂,利奈唑胺通过影响脂肪细胞的分化以及脂肪细胞因子的分泌对人体健康造成危害。

在抗生素广泛应用的今天,除去引起耐药性等副作用之外,像利奈唑胺这类抗生素也能够影响细胞的正常运转来危害人体的健康,如何去解决这些问题有待我们的进一步努力。

原始出处:

Laura Llobet, et al. Pharmacologic concentrations of linezolid modify oxidative phosphorylation function and adipocyte secretome. Redox Biol. 2017 May 31;13:244-254.doi: 10.1016/j.redox.2017.05.026.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1767144, encodeId=d5861e67144e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Feb 09 17:12:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917524, encodeId=892d191e524c8, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Feb 03 23:12:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374081, encodeId=eb5113e408159, content=<a href='/topic/show?id=f09732281ed' target=_blank style='color:#2F92EE;'>#利奈唑胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32281, encryptionId=f09732281ed, topicName=利奈唑胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Wed Jun 21 09:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400895, encodeId=678a1400895a1, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Wed Jun 21 09:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1767144, encodeId=d5861e67144e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Feb 09 17:12:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917524, encodeId=892d191e524c8, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Feb 03 23:12:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374081, encodeId=eb5113e408159, content=<a href='/topic/show?id=f09732281ed' target=_blank style='color:#2F92EE;'>#利奈唑胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32281, encryptionId=f09732281ed, topicName=利奈唑胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Wed Jun 21 09:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400895, encodeId=678a1400895a1, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Wed Jun 21 09:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
    2018-02-03 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1767144, encodeId=d5861e67144e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Feb 09 17:12:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917524, encodeId=892d191e524c8, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Feb 03 23:12:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374081, encodeId=eb5113e408159, content=<a href='/topic/show?id=f09732281ed' target=_blank style='color:#2F92EE;'>#利奈唑胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32281, encryptionId=f09732281ed, topicName=利奈唑胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Wed Jun 21 09:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400895, encodeId=678a1400895a1, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Wed Jun 21 09:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1767144, encodeId=d5861e67144e6, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Fri Feb 09 17:12:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917524, encodeId=892d191e524c8, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Feb 03 23:12:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374081, encodeId=eb5113e408159, content=<a href='/topic/show?id=f09732281ed' target=_blank style='color:#2F92EE;'>#利奈唑胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32281, encryptionId=f09732281ed, topicName=利奈唑胺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Wed Jun 21 09:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400895, encodeId=678a1400895a1, content=<a href='/topic/show?id=8fde8438079' target=_blank style='color:#2F92EE;'>#脂肪细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84380, encryptionId=8fde8438079, topicName=脂肪细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77712282976, createdName=shenxlcyp, createdTime=Wed Jun 21 09:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=)]

相关资讯

Lancet Infect Dis:新型抗生素tedizolid疗效不劣于利奈唑胺(ESTABLISH-2试验)

tedizolid(商品名:Sivextro,曾用名:TR-701)由Cubist制药公司开发,是一种恶唑烷酮类抗生素。Sivextro是一种前药,在体内可被磷酸酶迅速转化为具有生物活性的tedizolid。后者能够和细菌的核糖体50S亚基结合,从而抑制蛋白质的合成。尽管自2000 年辉瑞的同类抗菌素利奈唑胺获得美国FDA批准以后,至少有10个同类化合物进入临床,但Sivextro是第一个获得F

利奈唑胺对MRSA肺炎肥胖患者的疗效优于万古霉素

    抗微生物制剂和化疗跨学科会议上公布的一项美国全国回顾性队列分析显示,利奈唑胺对耐甲氧西林金黄色葡萄球菌(MRSA)肺炎肥胖患者的疗效优于万古霉素。     在该研究中,49例体重指数(BMI)≥30 kg/m2的患者通过静脉或口服方式接受600 mg(标准剂量)利奈唑胺治疗,每12 h给药1次。740例患者接受标准剂量万古霉素治

NEJM:药物利奈唑胺或可治疗广泛的耐药性结核病

刊登在国际著名杂志NEJM上的一项研究结果揭示了,药物利奈唑胺(linezolid)对于治疗广谱耐药性的结核病(TDR-TB)表现出了明显的疗效,而且很少有病人产生耐药性。该药物是治疗急性细菌感染的有效药物。然而接受该药物治疗的病人有82%都表现出了明显的不良事件,可能是由于服用药物的关系。 XDR-TB是一种至少对当前4种治疗肺结核的药物产生耐药的一种肺结核疾病,尽管该类疾病非常罕见,但是世界

Br J Clin Pharmacol:肾功能受损患者使用利奈唑胺是否调整剂量?

血小板减少症是利奈唑胺治疗最重要的不良反应之一。利奈唑胺诱导的血小板减少症的发生率差异不同,但提示与肾功能受损相关。2017年2月,发表在《Br J Clin Pharmacol》的一项研究调查了利奈唑胺的药效学机制(骨髓抑制或血小板破坏增加),以及肾功能受损对血小板减少症发生的影响。

CLIN PHARMACOKINET:对特定的败血症患者可增加利奈唑胺初始剂量使其获益

研究旨在评估败血症患者,糖尿病足部感染或囊性纤维化患者和健康志愿者血浆和间质空间流体(ISF)中的利奈唑胺药代动力学。联合分析对关节特征和疾病对血浆和靶位点暴露的影响与危重病人的剂量增强的益处。

利奈唑胺治疗是预测MRSA肺炎治疗成功的**可干预变量

Aisling R. Caffrey博士     研究者在全美退伍军人事务部(VA)医院MRSA 肺炎患者的队列中发现,利奈唑胺治疗是预测临床治疗成功的唯一可干预变量。     罗德岛大学药学院的Aisling R. Caffrey博士在年度抗微生物制剂与药物治疗跨学科会议上指出:“在美国,肺炎在感染疾病相关死亡原因中列首位,但对于M